Related Experiment Video

Updated: Oct 17, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

[Clinical implications of a new TSH receptor antibody assay (DYNOtest TRAKhuman) in autoimmune thyroid diseases]

J Meller1, I Schreivogel, A Bergmann

  • 1Abt. Nuklearmedizin, Georg-August-Universität Göttingen, Deutschland. jmeller@med.uni-goettingen.de

Nuklearmedizin. Nuclear Medicine
|March 22, 2000
PubMed
Abstract

Insights

A new human recombinant TSH-receptor assay (DYNOtest TRAKhuman) significantly improves Graves' disease diagnosis over conventional methods. This assay is also effective for detecting TSH-receptor antibodies (TRAKs) in autoimmune thyroiditis, offering superior diagnostic performance.

Area of Science:

  • Endocrinology
  • Immunology
  • Diagnostic Assay Development

Background:

  • Conventional radioreceptor-antibody-assays (RAAs) have limitations in detecting TSH-receptor antibodies (TRAKs), failing in 10-30% of Graves' disease (GD) patients.
  • Accurate detection of TRAKs is crucial for diagnosing and managing autoimmune thyroid diseases.
  • Existing assays may not adequately identify TRAKs in all patient subgroups, necessitating improved diagnostic tools.

Purpose of the Study:

  • To evaluate the diagnostic efficacy and clinical impact of a novel RRA, DYNOtest TRAKhuman, utilizing a human recombinant TSH-receptor.
  • To compare the performance of DYNOtest TRAKhuman against a conventional RRA for autoimmune thyroid disease diagnosis.
  • To assess the assay's utility in specific patient populations, including those with Graves' disease and autoimmune thyroiditis.

Main Methods:

  • Sera from 142 patients with Graves' disease (n=50) or autoimmune thyroiditis (n=92), and 55 controls were analyzed.
  • Samples were tested using both the DYNOtest TRAKhuman assay and a conventional TRAK-Assay.
  • Thyroid function tests and thyroid sonography were performed on all patients to correlate assay results with clinical findings.

Main Results:

  • The DYNOtest TRAKhuman assay demonstrated significantly superior performance in diagnosing Graves' disease compared to the conventional RRA (p < 0.00012).
  • The new assay showed improved detection rates, particularly in patients treated with thionamides (p < 0.003) and in diagnosing TRAK-positive autoimmune thyroiditis (p < 0.003).
  • Specificity was comparable between the DYNOtest TRAKhuman and the conventional assay, with only one false positive result in each for euthyroid goiter patients.

Conclusions:

  • The DYNOtest TRAKhuman assay is a superior diagnostic tool for Graves' disease compared to conventional TRAK-assays.
  • The assay provides equivalent specificity to conventional methods while enhancing diagnostic accuracy.
  • DYNOtest TRAKhuman offers significant advantages in the work-up of autoimmune thyroid diseases, particularly Graves' disease.

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.